股骨与胫骨肿瘤大块同种异体骨重建能否在植入后存活10年以上?
回顾性分析1986至2007年单中心198例股骨或胫骨原发骨肿瘤切除后行节段性大块同种异体骨重建的患者,平均随访192个月,最低随访10年。同种异体骨移除、关节置换或截肢的累积风险5年为36%、10年为40%、20年为44%。胫骨关节面型移植失败风险高于股骨关节面型及胫骨间插型,股骨骨折更常见、胫骨感染更常见。
要点
- 大块同种异体骨10年失败风险40%,20年44%,主要并发症为骨折、感染、不愈合。
- 胫骨关节面型移植失败风险最高,5、10、20年均为58%。
- 股骨骨折更常见,胫骨感染更常见,感染多导致早期移植移除。
核心结论
- 股骨或胫骨肿瘤大块同种异体骨重建在10年以上随访中仍有约40%的移植移除、关节置换或截肢风险。
- 感染是术后2至3年内移植移除最常见的原因,且更常见于胫骨移植。
- 骨折与更长期随访中的移植移除相关,且更常见于股骨移植。
研究设计与样本
- 单中心回顾性分析1986至2007年398例股骨或胫骨良恶性骨肿瘤患者,最终纳入198例接受节段性大块同种异体骨重建者。
- 纳入120例关节面型同种异体骨和78例节段间插型同种异体骨,其中股骨132例、胫骨66例。
- 平均年龄22岁(范围2-55岁),男性105例(53%),146例(74%)接受化疗。
- 32例(16%)在10年前死亡,其移植状态已知;其余166例随访至少10年,无失访。
- 采用多因素logistic回归分析移植移除、关节置换或截肢的风险因素,并以竞争风险分析计算5、10、20年终点风险。
主要发现
- 同种异体骨移除、关节置换或截肢的风险5年为36%(95% CI,30-43),10年为40%(95% CI,33-47),20年为44%(95% CI,37-51)。
- 骨折发生于15%(29例),感染14%(27例),不愈合12%(23例),肿瘤复发7%(13例)。
- 10年后仍有6例移植移除(4例骨折、1例感染、1例不稳定)和1例因第二恶性肿瘤截肢。
- 胫骨关节面型移植失败风险5、10、20年均为58%(95% CI,43-73),高于股骨关节面型(5年29%[95% CI,18-39],10年30%[95% CI,19-40],20年37%[95% CI,25-48];p=0.010)和胫骨间插型(5、10、20年均为26%[95% CI,7-45];p=0.020)。
- 股骨骨折发生率18%(95% CI,11-25)高于胫骨5%(95% CI,0-10)(p<0.010);胫骨感染发生率24%(95% CI,14-35)高于股骨4%(95% CI,0-8)(p<0.001)。
关键数值与推荐
- 同种异体骨使用指征包括良性或低级别肉瘤,以及高级别肉瘤对新辅助化疗有临床和影像学反应者。
- 排除同种异体骨-假体复合物53例、半髁关节面型同种异体骨46例、间插半柱状同种异体骨57例。
- 功能评估采用肌肉骨骼肿瘤协会(MSTS)-93评分系统。
临床怎么用
- 对于良性或低级别骨肿瘤患者,大块同种异体骨重建仍可作为保肢重建的选择之一。
- 胫骨关节面型同种异体骨重建失败风险较高,近15年来仅在儿童患者中使用该术式。
- 术后早期应重点监测感染(尤其胫骨),长期随访应关注骨折(尤其股骨)及移植失败。
局限性
- 本研究为单中心回顾性分析,无法与其他重建方式直接比较。
- 样本量有限,部分风险因素分析可能效能不足。
- 未分析移植骨长度百分比、钢板螺钉类型和数量、固定方式(髓内钉与钢板)等可能影响失败的因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Massive bone allografts have been used for limb salvage in patients undergoing bone tumor resections as an alternative to endoprostheses. Although several studies on massive allograft reconstructions for bone tumors reported that most complications occur in the first 3 years after surgery, there are no long-term reports on complications to substantiate this contention. We believe such information is important so that surgeons and patients can make more informed decisions when choosing a reconstructive method after tumor resection. QUESTIONS/PURPOSES: (1) What is the survival of allografts free from removal, amputation, or joint replacement in patients treated for bone tumors in the lower limb with a minimum of 10 years of followup? (2) What complications occur after 10 or more years of followup? (3) Are there factors associated with allograft survival, such as age, sex, the affected bone, reconstruction type (intercalary or osteoarticular allograft), tumor type (malignant or benign), failure type, and chemotherapy use? METHODS: We retrospectively analyzed the records of 398 patients treated in one center with benign or malignant bone tumors in the femur or tibia between 1986 and 2007. During the period in question, our general indications for using allografts (354 patients) included patients with benign or low-grade sarcomas and patients with high-grade sarcomas with clinical and imaging response to neoadjuvant chemotherapy. Other approaches such as endoprostheses (44 patients) were indicated if the patient received radiotherapy, in patients with high-grade sarcomas without clinical and imaging response to neoadjuvant chemotherapy, or with neurovascular tumor involvement. We excluded from the analysis 53 patients treated with allograft-prosthetic composites, 46 with hemicondylar osteoarticular allografts, and 57 with intercalary hemicylindrical allografts. The study was thus performed in 198 patients treated with segmental massive allografts in the long bones of the lower extremity (132 femurs and 66 tibias) after resection of a primary bone tumor, including 120 patients treated with osteoarticular and 78 with segmental intercalary allografts. A total of 32 (16%) of the 198 patients died before 10 years, and graft status was known in all of those patients; these patients were included (mean followup, 192 months; range, 1-370 months). All remaining 166 patients who were not known to have died before 10 years were accounted for at least 10 years after the allograft procedure (mean, 222 months; range, 120-370 months). No patient was lost to followup. The mean age was 22 years (range, 2-55 years); 105 patients were male (53%) and 93 were female. The predominant diagnoses were osteosarcoma (n = 125, 63%), giant cell tumor of bone (n = 27, 14%), and Ewing's sarcoma (n = 19, 10%). In all, 146 patients (74%) underwent chemotherapy. Selected variables were analyzed using multivariate logistic regression analyses to identify risk factors of allograft removal, joint replacement, or amputation. We performed competitive risk analysis with allograft removal, joint replacement, or amputation as the endpoint at 5, 10, and 20 years. Patient function was evaluated using the Musculoskeletal Tumor Society (MSTS)-93 scoring system. RESULTS: The risk of allograft removal, joint replacement, or amputation was 36% at 5 years (95% CI, 30-43), 40% at 10 years (95% CI, 33-47), and 44% at 20 years (95% CI, 37-51). Fractures occurred in 15% (29 patients), infection in 14% (27 patients), nonunion in 12% (23 patients) and tumor recurrence in 7% (13 patients). Thirty-two patients died of disease before 10 years; nine of these patients had a second surgery before death, eight had an amputation, and one underwent graft removal. Of the 166 patients who were still alive 10 years after the allograft procedure, 36 underwent allograft removal, six patients underwent joint replacement, and four had an amputation; however, after 10 years, six more allografts were removed (four due to fractures, one due to infection, and one due to instability), and another patient was amputated due to a second malignancy. After controlling for potentially confounding variables including death, we found that the risk of allograft removal, joint replacement, or amputation in osteoarticular tibial grafts (58% [95% CI, 43-73] at 5, 10, and 20 years) was higher than that of osteoarticular femur allografts (29% [95% CI, 18-39] at 5 years, 30% [95% CI, 19-40] at 10 years, 37% [95% CI, 25-48] at 20 years; p = 0.010) and tibia intercalary allografts (26% [95% CI, 7-45] at 5, 10 and 20 years; p = 0.020). Fractures occurred more frequently in the femur (18% [95% CI, 11-25]) than in the tibia (5% [95% CI, 0-10]; p < 0.010), and infections occurred more frequently in the tibia (24% [95% CI, 14-35]) than in the femur (4% [95% CI, 0-8]; p < 0.001). With the number of patients we had, we found no difference in the proportion of local recurrence in the tibia (12% [95% CI, 4-20]) compared with the femur (5% [95% CI, 1-9]; p < 0.053). CONCLUSIONS: Infections were the most common complications associated with allograft removal in the first 2 to 3 years after reconstruction and were more frequently associated with tibial allograft removal. Fractures were more commonly associated with graft removal with longer term followup and were more frequently associated with femoral allograft removal. Although we cannot directly compare our results with other types of reconstructions, we believe that allografts still have a role in the reconstruction of patients with a benign or low-grade bone tumor. Future studies in femoral allograft with longer followup should be performed to analyze factors that may explain why some grafts fail, such as the percent of the length of the bone resected, type and number of plates and screws used and type of fixation (rods versus plates). There was a higher incidence of graft removal in patients with proximal tibia osteoarticular allografts, which has led us to use this type of reconstruction only in pediatric patients over the last 15 years. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Aponte-Tinao LA, Ayerza MA, Albergo JI, et al. Do Massive Allograft Reconstructions for Tumors of the Femur and Tibia Survive 10 or More Years after Implantation? Clin Orthop Relat Res. 2020. PMID: 32168064. doi:10.1097/CORR.0000000000000806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。